Does High-Dose Thromboprophylaxis Improve Outcomes in COVID-19 Patients? A Meta-analysis of Comparative Studies.

non-ICU patients; (2) Therapeutic anticoagulation significantly decreased risk of thromboembolism in some of the available RCTs, especially among non-ICU patients; (3) bleeding events occurred more frequently with therapeutic anticoagulation in nonrandomized and randomized studies, although numbers did not reach statistical significance among RCTs; and (4) lack of mortality or morbidity benefit with intermediate-dose anticoagulation.

also in 111,027 other papers

There was a nonsignificant trend toward lower risk of thromboembolism with therapeutic-dose anticoagulation among RCTs (OR = 0.65, 95% CI, 0.39–1.09; Fig. 3 ).

also in 5,406 other papers